RTP Mobile Logo
LCU120

Interview with D Ross Camidge, MD, PhD

Topic 1: Case: A man in his mid-50s with metastatic non-small cell lung cancer (NSCLC) and an ALK rearrangement receives brigatinib as first-line therapy on the ALTA-1L trial
Topic 2: Results from the Phase III ALTA-1L and ALEX studies evaluating brigatinib or alectinib versus crizotinib for patients with advanced NSCLC and an ALK rearrangement
Topic 3: Side effects, dosing and quality of life with alectinib and brigatinib
Topic 4: Early onset pulmonary events associated with brigatinib
Topic 5: Activity of lorlatinib as second- or third-line therapy for NSCLC with an ALK rearrangement
Topic 6: Targeting the MET pathway for patients with NSCLC who experience disease progression on EGFR and ALK inhibitors
Topic 7: Treatment for patients with metastatic NSCLC and an ALK rearrangement who experience disease progression on an ALK inhibitor
Topic 8: Perspective on the potential identification of patients who might experience rapid disease progression on ALK inhibitors
Topic 9: Role of immune checkpoint inhibitors for patients with metastatic NSCLC and targetable mutations
Topic 10: PD-L1 expression as a predictive biomarker for patients with actionable alterations; approach to the use of immunotherapy
Topic 11: Treatment for patients with metastatic NSCLC and EGFR mutations who have experienced disease progression after targeted therapy
Topic 12: Case: A woman in her early 50s with metastatic NSCLC and an EGFR exon 20 insertion experiences disease progression after treatment with TAK-788 and whole-brain radiation therapy
Topic 13: Perspective on dementia associated with whole-brain radiation therapy
Topic 14: Guidelines from the Response Assessment in Neuro-Oncology Brain Metastases working group: Clinical trial design for systemic agents for brain metastases
Topic 15: Hippocampus sparing during radiation therapy for brain metastases
Topic 16: Targeting EGFR exon 20 insertions with TAK-788 and poziotinib
Topic 17: Incidence of NTRK alterations and treatment for patients with NTRK alterations
Topic 18: Case: A man in his mid-60s, a heavy smoker, with metastatic squamous cell lung carcinoma and MET amplification receives carboplatin/paclitaxel/pembrolizumab as first-line therapy
Topic 19: Choice of chemotherapy for patients with metastatic squamous cell lung cancer and targetable alterations
Topic 20: Efficacy of the selective MET inhibitors tepotinib and capmatinib for patients with advanced NSCLC and MET exon 14 skipping mutations
Topic 21: Prognosis and treatment for patients with NSCLC and KRAS mutations
Topic 22: Predictors of benefit with immunotherapy for patients with NSCLC
Topic 23: Ongoing investigation of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies for NSCLC
 
FACULTY
 
D Ross Camidge, MD, PhD
Professor of Medicine/Oncology
Joyce Zeff Chair in Lung Cancer Research
Director of Thoracic Oncology
University of Colorado Anschutz Medical Campus
Aurora, Colorado
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida